Meteora Capital’s ProKidney PROK Stock Holding History

Meteora Capital’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-42,299	Closed	-$421K	–	412
2022 Q2	$421K	Buy	+42,299	New	+$418K	0.08%	181

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Meteora Capital's PROK Position: Q3 2022 in Review

Meteora Capital sold out of ProKidney (PROK) in Q3 2022, closing a stake of 42,299 shares — an estimated $421K sold.

Meteora Capital first reported a position in PROK in Q2 2022 and held it in 1 quarter. The position peaked at $421K in Q2 2022. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

Meteora Capital reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
Meteora Capital sold 42,299 ProKidney shares in Q3 2022, an estimated $421K.
Meteora Capital first reported a position in ProKidney in Q2 2022 and held it in 1 quarter.
Meteora Capital's ProKidney position peaked at $421K in Q2 2022.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on Meteora Capital's 13F filing for Q3 2022, filed 14 Nov 2022.